Analysts Set $2.50 Price Target for AEterna Zentaris Inc. (AEZS)

AEterna Zentaris Inc. (NASDAQ:AEZS) (TSE:AEZ) has been given a consensus broker rating score of 1.00 (Strong Buy) from the two brokers that provide coverage for the company, Zacks Investment Research reports. Two research analysts have rated the stock with a strong buy rating.

Analysts have set a 12 month consensus price target of $2.50 for the company and are forecasting that the company will post ($0.41) earnings per share for the current quarter, according to Zacks. Zacks has also given AEterna Zentaris an industry rank of 169 out of 265 based on the ratings given to related companies.

Several equities research analysts have recently weighed in on the stock. Maxim Group reissued a “buy” rating and issued a $6.00 target price on shares of AEterna Zentaris in a research note on Wednesday, March 8th. Zacks Investment Research downgraded shares of AEterna Zentaris from a “hold” rating to a “sell” rating in a research note on Friday, May 12th. Finally, HC Wainwright reduced their price target on shares of AEterna Zentaris from $7.50 to $3.00 and set a “buy” rating on the stock in a research note on Wednesday, May 10th.

ILLEGAL ACTIVITY WARNING: “Analysts Set $2.50 Price Target for AEterna Zentaris Inc. (AEZS)” was first published by Transcript Daily and is the sole property of of Transcript Daily. If you are viewing this report on another site, it was stolen and reposted in violation of United States and international trademark and copyright law. The legal version of this report can be viewed at

Shares of AEterna Zentaris (NASDAQ:AEZS) traded down 1.451% on Friday, hitting $0.951. 159,571 shares of the stock traded hands. The firm’s market cap is $13.63 million. The stock has a 50-day moving average price of $0.96 and a 200 day moving average price of $2.54. AEterna Zentaris has a 52 week low of $0.78 and a 52 week high of $5.59.

AEterna Zentaris (NASDAQ:AEZS) (TSE:AEZ) last announced its earnings results on Monday, May 8th. The biopharmaceutical company reported ($0.31) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.33) by $0.02. AEterna Zentaris had a negative net margin of 2,732.69% and a negative return on equity of 425.52%. The business had revenue of $0.26 million for the quarter, compared to the consensus estimate of $0.85 million. During the same quarter in the prior year, the firm posted ($0.37) earnings per share. The business’s revenue for the quarter was up 8.3% on a year-over-year basis. Equities research analysts predict that AEterna Zentaris will post ($1.39) EPS for the current fiscal year.

An institutional investor recently raised its position in AEterna Zentaris stock. Morgan Stanley increased its stake in AEterna Zentaris Inc. (NASDAQ:AEZS) (TSE:AEZ) by 9.1% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 33,725 shares of the biopharmaceutical company’s stock after buying an additional 2,800 shares during the period. Morgan Stanley’s holdings in AEterna Zentaris were worth $102,000 at the end of the most recent quarter. 3.08% of the stock is owned by hedge funds and other institutional investors.

AEterna Zentaris Company Profile

Aeterna Zentaris Inc is a specialty biopharmaceutical company engaged in developing and commercializing treatments in oncology, endocrinology and women’s health. The Company operates through the biopharmaceutical segment. The Company is engaged in drug development activities and in the promotion of products for others.

Get a free copy of the Zacks research report on AEterna Zentaris (AEZS)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for AEterna Zentaris Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AEterna Zentaris Inc. and related companies with's FREE daily email newsletter.

Leave a Reply